Eris acquires Biocon’s branded formulations
The acquisition brings two major insulin brands, Basalog and Insugen, into the company’s fold, along with metabolic, oncology, and critical care products
image for illustrative purpose
New Delhi: Eris Lifesciences on Thursday said it has acquired commercial rights of Biocon Biologics’ India branded formulation business for Rs1,242 crore. The acquisition brings two major insulin brands – Basalog and Insugen – into the company’s fold, along with metabolic, oncology, and critical care products, the drug firm said in a statement. With the deal, Eris’ diabetes care franchise is expected to touch the Rs1,000 crore revenue mark, it added. The drug firm said it has signed a 10-year supply agreement with Biocon Biologics. As per the agreement, the Biocon product range will continue to be manufactured and supplied to Eris for commercialisation in India, it added.
